➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Johnson and Johnson
Dow
McKesson

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,820,694


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,820,694
Title:Beta-2-adrenoreceptor agonists
Abstract: Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
Inventor(s): Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin A (Horsham, GB), Beattie; David (Horsham, GB)
Assignee: Novartis AG (Basel, CH)
Application Number:12/577,855
Patent Claims: 1. A combination comprising (a) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one in free or salt or solvate form; and (b) an anticholinergic or antimuscarinic agent.

2. A combination according to claim 1, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate.

3. A combination according to claim 1, in which (b) is an anticholinergic or antimuscarinic agent selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide.

4. A combination according to claim 3, in which (b) is tiotropium bromide.

5. A pharmaceutical composition comprising a combination according to claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition according to claim 5, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylarnino)-1-hydroxy-ethyl]-8-hydroxy-1H-qui- nolin-2-one in free or salt or solvate form and in which (b) is, tiotropium bromide.

7. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment a therapeutically effective amount of a combination according to claim 1.

8. A method of treating a patient according to claim 7, in which the disease is chronic obstructive pulmonary or airways disease.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKesson
Johnson and Johnson
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.